483 research outputs found
Helium-3 and Helium-4 acceleration by high power laser pulses for hadron therapy
The laser driven acceleration of ions is considered a promising candidate for
an ion source for hadron therapy of oncological diseases. Though proton and
carbon ion sources are conventionally used for therapy, other light ions can
also be utilized. Whereas carbon ions require 400 MeV per nucleon to reach the
same penetration depth as 250 MeV protons, helium ions require only 250 MeV per
nucleon, which is the lowest energy per nucleon among the light ions. This fact
along with the larger biological damage to cancer cells achieved by helium
ions, than that by protons, makes this species an interesting candidate for the
laser driven ion source. Two mechanisms (Magnetic Vortex Acceleration and
hole-boring Radiation Pressure Acceleration) of PW-class laser driven ion
acceleration from liquid and gaseous helium targets are studied with the goal
of producing 250 MeV per nucleon helium ion beams that meet the hadron therapy
requirements. We show that He3 ions, having almost the same penetration depth
as He4 with the same energy per nucleon, require less laser power to be
accelerated to the required energy for the hadron therapy.Comment: 8 pages, 3 figures, 1 tabl
Light-Trap: A SiPM Upgrade for Very High Energy Astronomy and Beyond
With the development of the Imaging Atmospheric Cherenkov Technique (IACT),
Gamma-ray astronomy has become one of the most interesting and productive
fields of astrophysics. Current IACT telescope arrays (MAGIC, H.E.S.S, VERITAS)
use photomultiplier tubes (PMTs) to detect the optical/near-UV Cherenkov
radiation emitted due to the interaction of gamma rays with the atmosphere. For
the next generation of IACT experiments, the possibility of replacing the PMTs
with Silicon photomultipliers (SiPMs) is being studied. Among the main
drawbacks of SiPMs are their limited active area (leading to an increase in the
cost and complexity of the camera readout) and their sensitivity to unwanted
wavelengths. Here we propose a novel method to build a relatively low-cost
pixel consisting of a SiPM attached to a PMMA disc doped with a wavelength
shifter. This pixel collects light over a much larger area than a single
standard SiPM and improves sensitivity to near-UV light while simultaneously
rejecting background. We describe the design of a detector that could also have
applications in other fields where detection area and cost are crucial. We
present results of simulations and laboratory measurements of a pixel prototype
and from field tests performed with a 7-pixel cluster installed in a MAGIC
telescope camera.Comment: Proceedings of the 35th International Cosmic Ray Conference (ICRC
2017), Bexco, Busan, Korea. Id:81
Model-based predictions of protective HIV pre-exposure prophylaxis adherence levels in cisgender women
Most human immunodeficiency virus (HIV) infections occur in cisgender women in resource-limited settings. In women, self-protection with emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (FTC/TDF-PrEP) constitutes a major pillar of HIV prevention. However, clinical trials in women had inconsistent outcomes, sparking uncertainty about adherence requirements and reluctance in evaluating on-demand regimens. We analyzed data from published FTC/TDF-PrEP trials to establish efficacy ranges in cisgender women. In a âbottom-upâ approach, we modeled hypotheses in the context of risk-group-specific, adherenceâefficacy profiles and challenged those hypotheses with clinical data. We found that different clinical outcomes were related to the proportion of women taking the product, allowing coherent interpretation of the data. Our analysis showed that 90% protection was achieved when women took some product. We found that hypotheses of putative male/female differences were either not impactful or statistically inconsistent with clinical data. We propose that differing clinical outcomes could arise from pill-taking behavior rather than biological factors driving specific adherence requirements in cisgender women
Recommended from our members
Disinhibition in Risky Sexual Behavior in Men, but Not Women, during Four Years of Antiretroviral Therapy in Rural, Southwestern Uganda
Background: In resource-rich areas, risky sexual behavior (RSB) largely diminishes after initiation of anti-retroviral therapy, with notable exceptions among some populations who perceive a protected benefit from anti-retroviral therapy (ART). Yet, there is limited data about long-term trends in risky sexual behavior among HIV-infected people in sub-Saharan Africa after initiation of anti-retroviral therapy. Methods: We administered questionnaires every three months to collect sexual behavior data among patients taking ART in southwestern Uganda over four years of follow-up time. We defined RSB as having unprotected sex with an HIV-negative or unknown status partner, or unprotected sex with a casual partner. We fit logistic regression models to estimate changes in RSB by time on ART, with and without adjustment for calendar year and CD4 count. Results: 506 participants were enrolled between 2005 and 2011 and contributed a median of 13 visits and 3.5 years of observation time. The majority were female (70%) and median age was 34 years (interquartile range 29â39). There was a decrease in the proportion of men reporting RSB from the pre-ART visit to the first post-ART visit (16.2 to 4.3%, p<0.01) but not women (14.1 to 13.3%, p = 0.80). With each year of ART, women reported decreasing RSB (OR 0.85 per year, 95%CI 0.74â0.98, p = 0.03). In contrast, men had increasing odds of reporting RSB with each year of ART to near pre-treatment rates (OR 1.41, 95%CI 1.14â1.74, p = 0.001), which was partially confounded by changes in calendar time and CD4 count (AOR = 1.24, 95%CI 0.92â1.67, p = 0.16). Conclusions: Men in southwestern Uganda reported increasing RSB over four years on ART, to levels approaching pre-treatment rates. Strategies to promote long-term safe sex practices targeted to HIV-infected men on ART might have a significant impact on preventing HIV transmission in this setting
Optimizing Network Connectivity for Mobile Health Technologies in sub-Saharan Africa
Background: Mobile health (mHealth) technologies hold incredible promise to improve healthcare delivery in resource-limited settings. Network reliability across large catchment areas can be a major challenge. We performed an analysis of network failure frequency as part of a study of real-time adherence monitoring in rural Uganda. We hypothesized that the addition of short messaging service (SMS+GPRS) to the standard cellular network modality (GPRS) would reduce network disruptions and improve transmission of data. Methods: Participants were enrolled in a study of real-time adherence monitoring in southwest Uganda. In June 2011, we began using Wisepill devices that transmit data each time the pill bottle is opened. We defined network failures as medication interruptions of >48 hours duration that were transmitted when network connectivity was re-established. During the course of the study, we upgraded devices from GPRS to GPRS+SMS compatibility. We compared network failure rates between GPRS and GPRS+SMS periods and created geospatial maps to graphically demonstrate patterns of connectivity. Results: One hundred fifty-seven participants met inclusion criteria of seven days of SMS and seven days of SMS+GPRS observation time. Seventy-three percent were female, median age was 40 years (IQR 33â46), 39% reported >1-hour travel time to clinic and 17% had home electricity. One hundred one had GPS coordinates recorded and were included in the geospatial maps. The median number of network failures per person-month for the GPRS and GPRS+SMS modalities were 1.5 (IQR 1.0â2.2) and 0.3 (IQR 0â0.9) respectively, (mean difference 1.2, 95%CI 1.0â1.3, p-value<0.0001). Improvements in network connectivity were notable throughout the region. Study costs increased by approximately $1USD per person-month. Conclusions: Addition of SMS to standard GPRS cellular network connectivity can significantly reduce network connection failures for mobile health applications in remote areas. Projects depending on mobile health data in resource-limited settings should consider this upgrade to optimize mHealth applications
Empiric Deworming and CD4 Count Recovery in HIV-Infected Ugandans Initiating Antiretroviral Therapy
Background: There is conflicting evidence on the immunologic benefit of treating helminth co-infections (âdewormingâ) in HIV-infected individuals. Several studies have documented reduced viral load and increased CD4 count in antiretroviral therapy (ART) naĂŻve individuals after deworming. However, there are a lack of data on the effect of deworming therapy on CD4 count recovery among HIV-infected persons taking ART. Methodology/Principal Findings To estimate the association between empiric deworming therapy and CD4 count after ART initiation, we performed a retrospective observational study among HIV-infected adults on ART at a publicly operated HIV clinic in southwestern Uganda. Subjects were assigned as having received deworming if prescribed an anti-helminthic agent between 7 and 90 days before a CD4 test. To estimate the association between deworming and CD4 count, we fit multivariable regression models and analyzed predictors of CD4 count, using a time-by-interaction term with receipt or non-receipt of deworming. From 1998 to 2009, 5,379 subjects on ART attended 21,933 clinic visits at which a CD4 count was measured. Subjects received deworming prior to 668 (3%) visits. Overall, deworming was not associated with a significant difference in CD4 count in either the first year on ART (β = 42.8; 95% CI, â2.1 to 87.7) or after the first year of ART (β = â9.9; 95% CI, â24.1 to 4.4). However, in a sub-analysis by gender, during the first year of ART deworming was associated with a significantly greater rise in CD4 count (β = 63.0; 95% CI, 6.0 to 120.1) in females. Conclusions/Significance: Empiric deworming of HIV-infected individuals on ART conferred no significant generalized benefit on subsequent CD4 count recovery. A significant association was observed exclusively in females and during the initial year on ART. Our findings are consistent with recent studies that failed to demonstrate an immunologic advantage to empirically deworming ART-naĂŻve individuals, but suggest that certain sub-populations may benefit
Depression During Pregnancy and the Postpartum Among HIV-Infected Women on Antiretroviral Therapy in Uganda
Background: Among HIV-infected women, perinatal depression compromises clinical, maternal, and child health outcomes. Antiretroviral therapy (ART) is associated with lower depression symptom severity but the uniformity of effect through pregnancy and postpartum periods is unknown. Methods: We analyzed prospective data from 447 HIV-infected women (18â49 years) initiating ART in rural Uganda (2005â2012). Participants completed blood work and comprehensive questionnaires quarterly. Pregnancy status was assessed by self-report. Analysis time periods were defined as currently pregnant, postpartum (0â12 months post-pregnancy outcome), or nonâpregnancy-related. Depression symptom severity was measured using a modified Hopkins Symptom Checklist 15, with scores ranging from 1 to 4. Probable depression was defined as >1.75. Linear regression with generalized estimating equations was used to compare mean depression scores over the 3 periods. Results: At enrollment, median age was 32 years (interquartile range: 27â37), median CD4 count was 160 cells per cubic millimeter (interquartile range: 95â245), and mean depression score was 1.75 (s = 0.58) (39% with probable depression). Over 4.1 median years of follow-up, 104 women experienced 151 pregnancies. Mean depression scores did not differ across the time periods (P = 0.75). Multivariable models yielded similar findings. Increasing time on ART, viral suppression, better physical health, and ânever marriedâ were independently associated with lower mean depression scores. Findings were consistent when assessing probable depression. Conclusions: Although the lack of association between depression and perinatal periods is reassuring, high depression prevalence at treatment initiation and continued incidence across pregnancy and nonâpregnancy-related periods of follow-up highlight the critical need for mental health services for HIV-infected women to optimize both maternal and perinatal health
- âŚ